Genprex, Inc.

Genprex, Inc. company information, Employees & Contact Information

Explore related pages

Related company profiles:

Genprex, Inc. is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex’s technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Genprex’s oncology program utilizes its proprietary, non-viral ONCOPREX® Nanoparticle Delivery System, which the Company believes is the first systemic gene therapy delivery platform used for cancer in humans. ONCOPREX encapsulates the gene-expressing plasmids using lipid nanoparticles. The resultant product is administered intravenously, where it is then taken up by tumor cells that express tumor suppressor proteins that are deficient in the body. The Company’s lead product candidate, REQORSA® (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Both NSCLC clinical programs received a Fast Track Designation from the Food and Drug Administration. Genprex’s diabetes gene therapy approach is comprised of a novel infusion process that uses an endoscope and an adeno-associated virus (AAV) vector to deliver Pdx1 and MafA genes directly to the pancreas. In models of Type 1 diabetes, GPX-002 transforms alpha cells in the pancreas into functional beta-like cells, which can produce insulin but are distinct enough from beta cells to evade the body’s immune system. In a similar approach, GPX-003 for Type 2 diabetes, where autoimmunity is not at play, is believed to rejuvenate and replenish exhausted beta cells.

Company Details

Employees
23
Founded
-
Address
1601 Trinity St, Bldg B,
Phone
(512)537-7997
Email
in****@****rex.com
Industry
Biotechnology
HQ
Austin, Texas
Looking for a particular Genprex, Inc. employee's phone or email?

Genprex, Inc. Questions

News

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules - PR Newswire

Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules PR Newswire

Genprex (NASDAQ: GNPX) in registered direct offering $3.4M; warrants up to $6.6M - Stock Titan

Genprex (NASDAQ: GNPX) in registered direct offering $3.4M; warrants up to $6.6M Stock Titan

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - PR Newswire

Genprex Collaborators Report Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics PR Newswire

Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough - ts2.tech

Genprex (NASDAQ:GNPX) Stock Skyrockets 40% on Lung Cancer Gene Therapy Breakthrough ts2.tech

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics - Eastern Progress

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics Eastern Progress

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics - PR Newswire

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics PR Newswire

Genprex (NASDAQ: GNPX) expects $2.7M upfront; up to $5.4M more from short-term warrants - Stock Titan

Genprex (NASDAQ: GNPX) expects $2.7M upfront; up to $5.4M more from short-term warrants Stock Titan

10–33x tumor uptake: Genprex's REQORSA shows targeted TUSC2 delivery in preclinical poster on Oct 25 - Stock Titan

10–33x tumor uptake: Genprex's REQORSA shows targeted TUSC2 delivery in preclinical poster on Oct 25 Stock Titan

Genprex Achieves Major Clinical Milestones: CEO Reveals Ambitious Plans for Cancer and Diabetes Gene Therapies - Stock Titan

Genprex Achieves Major Clinical Milestones: CEO Reveals Ambitious Plans for Cancer and Diabetes Gene Therapies Stock Titan

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions - PR Newswire

Genprex Collaborators Present Research on Non-Viral Approach to Diabetes Gene Therapy Using Lipid Nanoparticle Delivery System at the 2025 American Diabetes Association 85th Scientific Sessions PR Newswire

Genprex to Participate at BIO 2025 International Convention - PR Newswire

Genprex to Participate at BIO 2025 International Convention PR Newswire

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting - PR Newswire

Genprex to Present Trial Design of Acclaim-3 Clinical Trial Evaluating Reqorsa® Gene Therapy in Small Cell Lung Cancer at 2025 ASCO Annual Meeting PR Newswire

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes - PR Newswire

Genprex Signs Sponsored Research Agreement with the University of Pittsburgh to Study Diabetes Gene Therapy in Type 1 and Type 2 Diabetes PR Newswire

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting - Yahoo Finance

Genprex Collaborators Present Positive Preclinical Data on Diabetes Gene Therapy at the ASGCT 28th Annual Meeting Yahoo Finance

Patent Protection Until 2037: Genprex Strengthens Reqorsa Cancer Therapy IP Portfolio Globally - Stock Titan

Patent Protection Until 2037: Genprex Strengthens Reqorsa Cancer Therapy IP Portfolio Globally Stock Titan

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting - PR Newswire

Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR Annual Meeting PR Newswire

Genprex Provides Update on Diabetes Gene Therapy Program - PR Newswire

Genprex Provides Update on Diabetes Gene Therapy Program PR Newswire

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer - Yahoo Finance

Genprex Collaborators Find NPRL2 Gene Therapy Using Oncoprex® Delivery System is a Potential Treatment for Anti-PD1 Resistant Non-Small Cell Lung Cancer Yahoo Finance

Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner - PR Newswire

Genprex Announces the Passing of its Co-Founder and Chief Executive Officer, Rodney Varner PR Newswire

Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes - PR Newswire

Genprex Announces Plans to Launch Separate Company to Focus on the Development of Gene Therapy to Treat Type-1 and Type-2 Diabetes PR Newswire

Genprex Makes Progress in 2 of 3 Lung Cancer Trials for Gene Therapy Reqorsa, but Drops the Other - CGTLive®

Genprex Makes Progress in 2 of 3 Lung Cancer Trials for Gene Therapy Reqorsa, but Drops the Other CGTLive®

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer - PR Newswire

Genprex Doses First Patient in Acclaim-3 Clinical Study of Reqorsa® Immunogene Therapy in Combination with Tecentriq® to Treat Small Cell Lung Cancer PR Newswire

Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer - Business Wire

Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer Business Wire

Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes - Business Wire

Genprex and University of Pittsburgh Sign Exclusive License Agreement for Potentially Curative Gene Therapy Candidate for Diabetes Business Wire

Genprex Announces Closing of Initial Public Offering - PR Newswire

Genprex Announces Closing of Initial Public Offering PR Newswire

Genprex to Participate in Upcoming Investor Conference in March | User | poteaudailynews.com - FinancialContent

Genprex to Participate in Upcoming Investor Conference in March | User | poteaudailynews.com FinancialContent

Genprex to Participate in Upcoming May Investor Conferences | User | poteaudailynews.com - FinancialContent

Genprex to Participate in Upcoming May Investor Conferences | User | poteaudailynews.com FinancialContent

User - FinancialContent

User FinancialContent

User - FinancialContent

User FinancialContent

User - FinancialContent

User FinancialContent

Genprex to Participate in CEO Roadshow Webinar Series | User | poteaudailynews.com - FinancialContent

Genprex to Participate in CEO Roadshow Webinar Series | User | poteaudailynews.com FinancialContent

Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer | User | poteaudailynews.com - FinancialContent

Genprex Expands Gene Therapy Oncology Pipeline to Include Small Cell Lung Cancer | User | poteaudailynews.com FinancialContent

Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer - FinancialContent

Genprex Initiates Site Recruitment for Acclaim-2 Clinical Trial for the Treatment of Non-Small Cell Lung Cancer FinancialContent

User - FinancialContent

User FinancialContent

User - FinancialContent

User FinancialContent

User - FinancialContent

User FinancialContent

User - FinancialContent

User FinancialContent

User - FinancialContent

User FinancialContent

Top Genprex, Inc. Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant